<DOC>
	<DOCNO>NCT02448004</DOCNO>
	<brief_summary>The primary objective study characterize absorption metabolic pathways JNJ-63623872 , excretion compound metabolite , single oral dose 14C-JNJ-63623872 healthy adult male participant .</brief_summary>
	<brief_title>Study Assess Absorption , Metabolism Excretion 14C-JNJ-63623872 After Single Dose Healthy Male Participants</brief_title>
	<detailed_description>This Phase 1 , open-label ( people know identity intervention ) , single dose study 6 healthy adult male participant characterize absorption , metabolism excretion 14C-JNJ-63623872 . The total study duration approximately 16 day per participant . The study consist 3 part : Screening ( , 28 day study commences Day 1 ) ; open-Label Treatment Phase ( , Day 1 ) ; Follow-up ( , Day 16 ) . All eligible participant receive 14C-JNJ-63623872 dose level 600 milligram . Participants enter study site Day -1 stay study site least Day 8 . Urine , feces , whole blood sample , plasma , nasal mucus saliva sample collect Day 8 . Unchanged JNJ-63623872 determined plasma , feasible , saliva . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Participants must agree comply contraceptive measure mention protocol Must nonsmoker least 3 month prior screen Must Body Mass Index ( BMI ; weight kilogram divide square height meter ) 18.0 30.0 kilogram/meter square , extremes include Must sign Informed consent form indicate understand purpose procedure require study willing participate study start screen activity Must willing/able adhere prohibition restriction specify protocol study procedure Must normal 12lead ECG ( base mean value triplicate parameter ) screen Day 1 predose include : 1 ) . normal sinus rhythm ( heart rate 45 100 beat per minute [ bpm ] , extremes include ) ; 2 ) . QT interval correct heart rate accord Fridericia ( QTcF ) interval less equal ( &lt; = ) 450 millisecond ( m ) ; 3 ) . QRS interval low 120 m ; 4 ) . PR interval &lt; = 220 m Participants past history heart arrhythmia ( extrasystoli clinically significant opinion investigator , tachycardia rest ) risk factor Torsade de Pointes syndrome Participants one episode constipation ( le 1 stool per 3 day ) last 2 month , one episode diarrhea ( 3 stool per day ) last 2 month Participants history reason believe subject history drug alcohol abuse within past 5 year Participants positive urine drug test study screen Day 1 . Urine test presence amphetamine , benzodiazepine , cocaine , cannabinoids , opioids , methadone barbiturates Participants document human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection study screen Participants current hepatitis A infection ( confirm hepatitis A antibody immunoglobulin M ( [ IgM ] ) , hepatitis B virus ( HBV ) infection ( confirm hepatitis B surface antigen [ HbsAg ] ) , hepatitis C virus ( HCV ) infection ( confirm HCV antibody ) study screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-63623872</keyword>
	<keyword>14C-JNJ-63623872</keyword>
</DOC>